Platelet-Like Particle Development

This contract focuses on the design and validation of synthetic or bioengineered particles that replicate platelet functions critical in trauma scenarios, including clot initiation, adhesion, and aggregation. The work involves developing these platelet-like particles and conducting in vivo testing to assess their efficacy and safety in mimicking natural platelet behavior for potential therapeutic applications. The contract is issued by the Defense Advanced Research Projects Agency under the Department of Defense, aligning with efforts to enhance trauma care through advanced bioengineering solutions. The opportunity is identified under NAICS code 325412, indicating a focus on pharmaceutical preparation manufacturing, and is categorized as a subcontract opportunity. The contract was posted on May 1, 2026, with a response deadline of May 19, 2026. Although specific details about the place of performance, point of contact, and set-aside status are not provided, the contract aims to support innovative research targeting critical needs in trauma treatment, leveraging bioengineered alternatives to natural platelets for improved survival and patient outcomes in military or civilian settings.